Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Cost Sharing Cap May Have Broadest Benefit For Jakafi, Revlimid, Pomalyst, Imbruvica Users

Executive Summary

A cap set at $2,000 would help nearly 1 million more seniors than a cap set at $3,100, according to new study by Kaiser Family Foundation. Either competing legislative proposal would probably be welcomed by pharma industry as way to defuse pricing debate.

You may also be interested in...



Drug Pricing Reform As Legislative ‘Pay For’ Gaining Momentum But What About Part D Redesign?

Association for Accessible Medicines makes a case for lowering prices in Part D through benefit design reforms enabling quicker and better access to first generics.

FDA’s Real-World Evidence Project Finds That Pragmatic Clinical Trials Are Easier To DUPLICATE

Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.

Preapproval Information Exchange Between Sponsors, Insurers Clarified In House User Fee Bill

By codifying FDA guidance, pending legislation aims to encourage industry to become more comfortable with even unsolicited communications to payers about investigational drugs.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel